13 July 2022
Continued sustained growth associated with the company’s sequencing platform in Évry and long-term contracts Strong revenue growth linked with microbiology sequencing
Evry, France, Wednesday July 13th 2022, 7.30am – IntegraGen (FR0010908723 – ALINT ), an OncoDNA Group company specializing in the decryption of the human genome which performs (…) »
29 April 2022
Positive EBITDA and net result Large increase in services delivered for the SeqOIA GCS and the P2M platform operated for Institut Pasteur Limited negative impact from the pandemic along the year Outlook: continued revenues growth for 2022 based on orders book
Évry, France, april 29TH 2022 – 6.00pm (…) »
14 January 2022
Significant increase in services delivered by SeqOIA and the Mutualized Microbiology (P2M) platform operated on behalf of the Institut Pasteur Stability of sequencing services provided by the Evry laboratory
EVRY, FRANCE, FRIDAY 14 JANUARY 2021, 7.30 – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA group (…) »
16 July 2021
Slight revenue growth despite the impact of the pandemic during the first half of the year. Strong increase in order intake sets the stage for an anticipated dynamic growth during the second half of the 2021.
EVRY, FRANCE, FRIDAY 16 JULY 2021, 7.30AM – IntegraGen (FR0010908723 – ALINT (…) »
12 January 2021
IntegraGen announced today its unaudited business figures for the year 2020.
2020 revenue amounted to 9.0 M € versus 8.1 M € in 2019, an increase of 10% over 12 months. Increased sequencing services reported for company’s Evry lab and at outsourced platforms run by the company for the SeqOIA (…) »
18 September 2020
IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020.
Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and confirms (…) »
16 September 2020
This press release was prepared and distributed by OncoDNA S.A. in accordance with the provisions of Articles 231-27 1 ° and 2 ° and 231-28 of the general regulations of the Autorité des marchés financiers (the “AMF”).
01 September 2020
IntegraGen’s Combined General Assembly for 2020 will be held on September 17, 2020 at 2 p.m. at the company’s headquarters which is located at Génopole Campus 1,Genavenir 8, Porte 840, 5 rue Henri Desbruères – 91000 Evry, France
Click here for more (…) »
09 July 2020
Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…) »
09 July 2020
IntegraGen announced unaudited sales for the first half of 2020 were 4,706 k€, an increase of 13% compared to the first half of 2019 and 15% on a like-for-like basis taking into account the sale of the company’s diagnostic business at the start of 2020. The growth in sales (…) »